Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Net Margin: 2020-2025

Historic Net Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 47.04%.

  • Apellis Pharmaceuticals' Net Margin rose 7623.00% to 47.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.43%, marking a year-over-year increase of 3940.00%. This contributed to the annual value of -25.32% for FY2024, which is 10797.00% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Net Margin stood at 47.04%, which was up 299.04% from -23.63% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Margin peaked at 4,399.02% during Q1 2021, and registered a low of -35,183.15% during Q2 2021.
  • Moreover, its 3-year median value for Net Margin was -38.56% (2024), whereas its average is -77.10%.
  • In the last 5 years, Apellis Pharmaceuticals' Net Margin slumped by 3,694,016bps in 2021 and then skyrocketed by 3,422,752bps in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Margin (Quarterly) stood at -245.37% in 2021, then tumbled by 48,706bps to -732.43% in 2022, then spiked by 67,192bps to -60.51% in 2023, then surged by 4,342bps to -17.09% in 2024, then spiked by 7,623bps to 47.04% in 2025.
  • Its last three reported values are 47.04% in Q3 2025, -23.63% for Q2 2025, and -55.29% during Q1 2025.